Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.

导出 LinkOut

翻译打印收藏纠错

作者： Shichao,Wang ^[1] ; Zhiyue,Li ^[2] ; Shaobing,Gao ^[3]

作者单位： The Fifth Affiliated Hospital of Zhengzhou University, No. 3 Kangfu Front Street, 450052, Zhengzhou, China. shi_wang01@163.com. ^[1] The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China. ^[2] The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China. gaoshaobing@zju.edu.cn. ^[3]

关键词 CC-90009 CRISPR-Cas9 screening CRL4CRBN E3 ligase Immunomodulatory drugs Multiple myeloma PROTACs Ubiquitination

DOI 10.1186/s40364-021-00297-6

PMID 34090534

发布时间 2021-06-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Biomarker research

2021年9卷1期

43页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.

Biomarker research

相似文献

Biomarker research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.

Biomarker research

相似文献

Biomarker research

相关期刊

检索历史清除